Atossa Therapeutics Inc.

4.6200.00Vol 8.01M1Y Perf 48.69%
Jun 15th, 2021 16:00 DELAYED
BID4.63 ASK4.68
Open4.63 Previous Close4.62
Pre-Market- After-Market4.56
 - -  -0.06 -1.30%
Target Price
6.00 
Analyst Rating
Strong Buy 1.00
Potential %
29.87 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
 —    -
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Market Cap558.21M 
Earnings Rating
Buy
Price Range Ratio 52W %
63.39 
Earnings Date
12th May 2021

Today's Price Range

4.444.80

52W Range

0.81006.82

5 Year PE Ratio Range

-0.4000-0.5000

Summary:

Buy

Technical Indicators: Neutral
Moving Averages: Strong Buy
Performance
1 Week
5.00%
1 Month
59.31%
3 Months
69.85%
6 Months
381.25%
1 Year
48.69%
3 Years
86.29%
5 Years
-91.44%
10 Years
-

TickerPriceChg.Chg.%
ATOS4.620.00000.00
AAPL129.64-0.8400-0.64
GOOG2 520.66-6.3800-0.25
MSFT258.36-1.5300-0.59
XOM64.332.26003.64
WFC45.460.31000.69
JNJ164.49-0.8800-0.53
FB336.75-0.0200-0.01
GE13.540.07000.52
JPM155.18-2.3900-1.52
Earnings HistoryEstimateReportedSurprise %
Q01 2021--0.04-
Q03 2020--0.34-
Q02 2020--0.43-
Q01 2020--0.32-
Q04 2019--0.26-
Q03 2019--0.36-
Q02 2019--0.80-
Q01 2019--0.62-
Earnings Per EndEstimateRevision %Trend
12/2018 QR-0.65-16.07Negative
12/2018 QR-0.5636.36Positive
12/2019 FY-1.280.00-
12/2020 FY-0.7749.01Positive
Next Report Date-
Estimated EPS Next Report-
Estimates Count-
EPS Growth Next 5 Years %-
Volume Overview
Volume8.01M
Shares Outstanding120.82M
Trades Count27.85K
Dollar Volume60.95M
Avg. Volume19.75M
Avg. Weekly Volume22.96M
Avg. Monthly Volume18.98M
Avg. Quarterly Volume13.08M

Atossa Therapeutics Inc. (NASDAQ: ATOS) stock closed at 4.62 per share at the end of the most recent trading day (a 0% change compared to the prior day closing price) with a volume of 8.08M shares and market capitalization of 558.21M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 6 people. Atossa Therapeutics Inc. CEO is Steven C. Quay.

The one-year performance of Atossa Therapeutics Inc. stock is 48.69%, while year-to-date (YTD) performance is 386.32%. ATOS stock has a five-year performance of -91.44%. Its 52-week range is between 0.81 and 6.82, which gives ATOS stock a 52-week price range ratio of 63.39%

Atossa Therapeutics Inc. currently has a PE ratio of -2.60, a price-to-book (PB) ratio of 3.73, a price-to-sale (PS) ratio of -, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -29.84%, a ROC of -30.43% and a ROE of -30.30%. The company’s profit margin is -%, its EBITDA margin is -%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.

Of the last four earnings reports from Atossa Therapeutics Inc., there were 0 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $0.00 for the next earnings report. Atossa Therapeutics Inc.’s next earnings report date is -.

The consensus rating of Wall Street analysts for Atossa Therapeutics Inc. is Strong Buy (1), with a target price of $6, which is +29.87% compared to the current price. The earnings rating for Atossa Therapeutics Inc. stock is Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Atossa Therapeutics Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Atossa Therapeutics Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 23.80, ATR14 : 0.66, CCI20 : 58.83, Chaikin Money Flow : 0.01, MACD : 0.53, Money Flow Index : 74.76, ROC : 45.28, RSI : 59.92, STOCH (14,3) : 43.73, STOCH RSI : 0.15, UO : 51.31, Williams %R : -56.27), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Atossa Therapeutics Inc. in the last 12-months were:

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
1 (100.00 %)
1 (100.00 %)
1 (100.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.00
Strong Buy
1.00
Strong Buy
1.00

Atossa Therapeutics Inc.

Atossa Therapeutics Inc is a clinical-stage pharmaceutical company operating in the US. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer and other breast conditions. The clinical-Stage Programs of the company includes delivery of therapeutics through microcatheters which delivers a number of therapeutics to the ducts in the breast, the site of the majority of early breast cancers and fulvestrant Delivered through microcatheters which delivers fulvestrant as a potential treatment of ductal carcinoma in-situ (DCIS) and breast cancer. In addition, the company involves in the process of evaluating additional potential indications of endoxifen and other therapeutic candidates to treat breast conditions, including breast cancer.

CEO: Steven C. Quay

Telephone: +1 206 325-6068

Address: 107 Spring Street, Seattle 98104, WA, US

Number of employees: 6

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

68%32%

Bearish Bullish

55%45%

Bearish Bullish

55%45%

News

Stocktwits